Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia
10.3760/cma.j.cn121090-20231007-00160
- VernacularTitle:异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床结局
- Author:
Xiaohui ZHANG
1
;
Jianying ZHOU
Author Information
1. 北京大学人民医院、北京大学血液病研究所、国家血液系统疾病临床医学研究中心、造血干细胞移植北京市重点实验室，北京 100044
- Keywords:
Chronic myelomonocytic leukemia;
Allogeneic hematopoietic stem cell transplantation;
Clinical outcomes
- From:
Chinese Journal of Hematology
2024;45(1):18-21
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myelomonocytic leukemia (CMML) is a clonal disease derived from bone marrow hematopoietic stem cells, with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo- HSCT) is one of the curable methods for CMML. The outcome of patient transplantation is influenced by various factors such as disease characteristics and comorbidities. Based on the existing prognostic stratification system, screening suitable CMML patients for transplantation and early transplantation is beneficial for their long-term survival. Doctors can evaluate the survival status of CMML patients after transplantation based on the newly developed transplant prognosis model and make targeted medical decisions.
